Phase II Pilot Study of Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer
Latest Information Update: 18 Nov 2024
Price :
$35 *
At a glance
- Drugs Durvalumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 04 Apr 2023 Status changed from not yet recruiting to recruiting.
- 31 Jan 2023 New trial record